- Report
- August 2024
- 175 Pages
Global
From €4753EUR$5,000USD£3,993GBP
- Report
- July 2024
- 110 Pages
Global
From €4516EUR$4,750USD£3,794GBP
- Report
- October 2024
- 194 Pages
Global
From €3370EUR$3,545USD£2,831GBP
€3745EUR$3,939USD£3,146GBP
- Report
- January 2025
- 120 Pages
Global
From €2367EUR$2,490USD£1,989GBP
- Report
- March 2025
- 184 Pages
Global
From €4706EUR$4,950USD£3,953GBP
- Report
- March 2025
- 93 Pages
Global
From €5324EUR$5,600USD£4,472GBP
- Report
- March 2025
- 196 Pages
Global
From €5324EUR$5,600USD£4,472GBP
- Report
- February 2025
- 200 Pages
Global
From €4268EUR$4,490USD£3,586GBP
- Report
- February 2025
- 200 Pages
Global
From €4268EUR$4,490USD£3,586GBP
- Report
- January 2025
- 200 Pages
Global
From €4268EUR$4,490USD£3,586GBP
- Report
- August 2024
- 143 Pages
Global
From €2851EUR$2,999USD£2,395GBP
- Report
- August 2024
- 150 Pages
Global
From €3565EUR$3,750USD£2,995GBP
- Report
- January 2025
- 144 Pages
Global
From €3755EUR$3,950USD£3,155GBP
- Report
- February 2025
- 186 Pages
Global
From €4278EUR$4,500USD£3,594GBP
- Report
- February 2025
- 182 Pages
Global
From €4278EUR$4,500USD£3,594GBP
- Report
- October 2023
- 157 Pages
Global
From €4421EUR$4,650USD£3,714GBP
- Report
- October 2021
- 154 Pages
Global
From €5276EUR$5,550USD£4,432GBP
- Report
- December 2023
- 111 Pages
Global
From €5656EUR$5,950USD£4,752GBP
- Report
- February 2024
- 125 Pages
Global
From €5656EUR$5,950USD£4,752GBP
- Report
- September 2023
- 180 Pages
Global
From €5656EUR$5,950USD£4,752GBP

Low Molecular Weight Heparin (LMWH) is a class of anticoagulant drugs used to prevent and treat thromboembolic disorders, such as deep vein thrombosis and pulmonary embolism. LMWH is a form of heparin, a naturally occurring anticoagulant, that has been modified to reduce its molecular weight and increase its bioavailability. LMWH is administered subcutaneously and has a longer half-life than unfractionated heparin, allowing for once-daily dosing. LMWH is also associated with fewer side effects than unfractionated heparin, making it a preferred treatment for cardiovascular diseases.
The LMWH market is a growing segment of the cardiovascular drugs market, with a wide range of products available. LMWH is used in a variety of clinical settings, including the prevention and treatment of thromboembolic disorders, the prevention of post-operative thrombosis, and the treatment of unstable angina and acute coronary syndrome.
Some of the major companies in the LMWH market include Sanofi, Pfizer, Bayer, and Bristol-Myers Squibb. Show Less Read more